On September 9, 2021, a panel of experts convened to discuss the use of immunoglobulin (Ig) therapies, detail the therapeutic benefits of Ig therapies for various disease states, offer practitioner insights on the impact of the COVID-19 global pandemic on patient treatment, and discuss how policies can play a role in optimal patient treatment with Ig therapies. The following key takeaways emerged from the discussion:

• Ig is used to treat immune deficiencies and other conditions that involve the immune system.

• The majority of Ig therapy use (approximately 65%) is as treatment for U.S. Food and Drug Administration (FDA) approved indications and the rest is as treatment for other conditions that are supported by scientific or practice based evidence.